NCT04195269 is a Phase 2 clinical trial of Test Article in Osteoarthritis, Knee, sponsored by Pure Green.

Who is sponsoring NCT04195269?

NCT04195269 is sponsored by Pure Green.

What drugs are being tested in NCT04195269?

Interventions in NCT04195269: Test Article.

What condition does NCT04195269 study?

NCT04195269 studies Osteoarthritis, Knee, Pain.

Is NCT04195269 still recruiting?

NCT04195269 is currently status unknown. Last updated 14 April 2020.

Last reviewed 2020-04-14 · How we verify

NCT04195269

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Osteoarthritis of the Knee Pain Study Using a CBD and THC Sublingual Tablet

Status unknown Phase 2 Last updated 14 April 2020

What this trial tests

Phase 2 trial testing Test Article in Osteoarthritis, Knee in 30 participants. Status unknown.

Timeline

20 April 2020

Primary endpoint
30 June 2020

15 July 2020

Quick facts

Lead sponsor	Pure Green
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	20 April 2020
Primary completion	30 June 2020
Estimated completion	15 July 2020
Sites	1 location across United States

Drugs / interventions tested

Test Article — full drug profile →

Conditions studied

Osteoarthritis, Knee — all drugs for Osteoarthritis, Knee →
Pain — all drugs for Pain →

Sponsor

Pure Green — full company profile →

Who can join

21 and older, any sex, with Osteoarthritis, Knee or Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective Phase 2, drug controlled, open-label study to evaluate the safety and efficacy of Pure Green sublingual tablets for the treatment of pain associated with osteoarthritis of the knee.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain.
Stella B, Baratta F, Della Pepa C, Arpicco S, et al · · 2021 · cited 103× · PMID 34480749 · DOI 10.1007/s40265-021-01579-x
Challenges and opportunities of pharmacological interventions for osteoarthritis: A review of current clinical trials and developments.
Vrouwe JPM, Burggraaf J, Kloppenburg M, Stuurman FE. · · 2021 · cited 16× · PMID 36474768 · DOI 10.1016/j.ocarto.2021.100212
Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain).
Boehnke KF, Häuser W, Fitzcharles MA. · · 2022 · cited 9× · PMID 35503198 · DOI 10.1007/s11926-022-01077-3
Cannabinoids, Inner Ear, Hearing, and Tinnitus: A Neuroimmunological Perspective.
Perin P, Mabou Tagne A, Enrico P, Marino F, et al · · 2020 · cited 8× · PMID 33329293 · DOI 10.3389/fneur.2020.505995

Verify or expand the search:

Other recruiting trials for Osteoarthritis, Knee

Currently open trials in the same condition.

NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT06488144 — Rehabilitation for Arthritis of The Knee: mainTaining Improvement for Veterans · Phase 3 · recruiting
NCT07386561 — Virtual Reality Therapy and Non-Sleep Deep Rest Relaxation After Joint Arthroplasty · NA · active not recruiting
NCT07514598 — Effect of J-Shaped Incision After Total Knee Arthroplasty (J-TKA) · NA · active not recruiting
NCT07058623 — Nurse-Led Telehealth vs In-Person Follow-Up After Total Knee Replacement · NA · recruiting

Other Pure Green trials

Trials by the same sponsor.

NCT04992962 — Cannabinoid Tablets for the Treatment of Pain From Osteoarthritis of the Knee · Phase 2 · unknown
NCT04679545 — Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet · Phase 2 · unknown
NCT04193631 — Low Dose of Cannabidiol (CBD) to Treat Mild to Moderate Musculoskeletal Pain · Phase 1 · completed
NCT04088929 — The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Periphera · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04195269 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pure Green
Last refreshed: 14 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04195269.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing